The role of bisphosphonates in breast cancer

Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. Lyon: IARCPress; 2001: Accessed 2004. Coleman, 2001, Metastatic bone disease, Cancer Treat Rev, 27, 165, 10.1053/ctrv.2000.0210 Coleman, 1997, Skeletal complications of malignancy, Cancer, 80, 1588, 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G Lipton, 2000, Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases, Cancer, 88, 1082, 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z Rosen, 2003, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma, Cancer, 98, 1735, 10.1002/cncr.11701 Major, 2002, Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints, Am J Clin Oncol, 25, S10, 10.1097/00000421-200212001-00003 Johnson, 2003, End points and United States Food and Drug Administration approval of oncology drugs, J Clin Oncol, 21, 1404, 10.1200/JCO.2003.08.072 Williams, 2004, Assessing tumor-related signs and symptoms to support cancer drug approval, J Biopharm Stat, 14, 5, 10.1081/BIP-120028503 Lipton, 2003, Management of metastatic bone disease and hypercalcemia of malignancy, Am J Cancer, 2, 427, 10.2165/00024669-200302060-00004 Green, 1994, Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound, J Bone Miner Res, 9, 745, 10.1002/jbmr.5650090521 Body, 2003, Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases, Ann Oncol, 14, 1399, 10.1093/annonc/mdg367 Body, 2004, Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease, Br J Cancer, 90, 1133, 10.1038/sj.bjc.6601663 Hortobagyi, 1998, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol, 16, 2038, 10.1200/JCO.1998.16.6.2038 Theriault, 1999, Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions, J Clin Oncol, 17, 846, 10.1200/JCO.1999.17.3.846 Cook, 2001, Methodology for treatment evaluation in patients with cancer metastatic to bone, J Natl Cancer Inst, 93, 534, 10.1093/jnci/93.7.534 Andersen, 1982, Cox's regression model for counting processes, Ann Stat, 10, 1100, 10.1214/aos/1176345976 Ghosh, 2000, Nonparametric analysis of recurrent events and death, Biometrics, 56, 554, 10.1111/j.0006-341X.2000.00554.x Cook, 1997, Marginal analysis of recurrent events and a terminating event, Stat Med, 16, 911, 10.1002/(SICI)1097-0258(19970430)16:8<911::AID-SIM544>3.0.CO;2-I Prentice, 1981, On the regression analysis of multivariate failure time data, Biometrika, 68, 373, 10.1093/biomet/68.2.373 Wei, 1989, Regression analysis of multivariate incomplete failure time data by modeling marginal distributions, J Amer Stat Assoc, 84, 1065, 10.1080/01621459.1989.10478873 Rosen, 2004, Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion, Cancer, 100, 36, 10.1002/cncr.11892 Paterson, 1993, Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer, J Clin Oncol, 11, 59, 10.1200/JCO.1993.11.1.59 Kristensen, 1999, Oral clodronate in breast cancer patients with bone metastases, J Intern Med, 246, 67, 10.1046/j.1365-2796.1999.00507.x Hortobagyi, 1996, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N Engl J Med, 335, 1785, 10.1056/NEJM199612123352401 Rosen, 2001, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma, Cancer J, 7, 377 Conte, 1996, Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate, J Clin Oncol, 14, 2552, 10.1200/JCO.1996.14.9.2552 Hultborn, 1999, Efficacy of pamidronate in breast cancer with bone metastases, Anticancer Res, 19, 3383 Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane Review). In: The Cochrane Library, Issue 1. Hoboken, NJ: Wiley, 2004. Tubiana-Hulin, 2001, [Double-blind controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases], Bull Cancer, 88, 701 Major, 2000, Oral bisphosphonates, Cancer, 88, 6, 10.1002/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D Diel, 1998, Reduction in new metastases in breast cancer with adjuvant clodronate treatment, N Engl J Med, 339, 357, 10.1056/NEJM199808063390601 Powles, 2002, Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer, J Clin Oncol, 20, 3219, 10.1200/JCO.2002.11.080 Kanis, 1996, Clodronate decreases the frequency of skeletal metastases in women with breast cancer, Bone, 19, 663, 10.1016/S8756-3282(96)00285-2 Lipton A. Bisphosphonate therapy for patients with osteolytic and osteoblastic bone metastases from breast or prostate cancer. Progress in Breast Cancer Research Hauppauge, NY: Nova Science Publishers, Inc; submitted. Rosen LS, Coleman RE, Gordon D, et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases. Presented at: St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer 8th International Conference; March 12–15, 2003; St. Gallen, Switzerland (poster 100). Major, 2003, Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone, Proc Am Soc Clin Oncol, 22, 762 Lipton A, Dewar R, Conte PF, Zheng M. Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases. Presented at: 4th European Breast Cancer Conference; March 16–19, 2004; Hamburg, Germany (poster 296). Diel, 2004, Low nephrotoxicity of Ibandronate, Bone, 34, S77 Bell, 2004, Ibandronate does not affect time to renal function deterioration over 2 years of treatment, Bone, 34, S75